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Abstract: When properly used, paraquat (PQ) is a widely used
bipyridil herbicide with a good safety record. Most cases of PQ
poisoning result from intentional ingestion, with death resulting
from hypoxemia secondary to lung fibrosis in moderate to severe
poisonings. With high ingestion volumes (>50 mL of a 20% wt/vol
formulation), death results from multiple organ failure and
cardiovascular collapse within 1 week after intoxication. The
present report describes a successful clinical case regarding the
intoxication of a 15-year-old girl by a presumed lethal dose of PQ.
The adolescent ingested approximately 50 mL of a commercialized
concentrate (20% wt/vol of dichloride salt) formulation of PQ. High
serum and urinary levels of PQ confirmed the bad prognosis.
However, the therapeutic protocol followed in the present clinical
case led to a positive outcome. Besides the measures for decreasing
PQ absorption and increasing its elimination, other protective
procedures were applied in aiming to reduce the production of
reactive oxygen species (ROS), to scavenge ROS, to repair ROS-
induced lesions, and to reduce inflammation. The status-of-the-art
concerning the biochemical and toxicological aspects of PQ
poisoning and the pharmacologic basis of the respective treatment
is also presented.
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S ince its introduction in agriculture in 1962,
1 the
widespread nonselective contact herbicide paraquat
(PQ), used as desiccant and defoliant in a variety of crops,
has caused thousands of deaths from both accidental and
voluntary ingestion, as well as from dermal exposure. It may
be considered as one of the most toxic poisons frequently used
for suicide attempts. A large oral dose of PQ (>30 mg kg1
in humans) rapidly leads to death from multiorgan fail-
ure, with lung damage consisting of disruption of alveolar
epithelial cells, hemorrhage, edema, and infiltration of inflam-
matory cells into the interstitial and alveolar spaces.1 Smaller
doses of PQ (from 16 mg kg1) may also lead to death, but this
occurs after several days as a result of a progressive lung
fibrosis, by proliferation of fibroblasts, and excessive collagen
deposition, showing that the main target organ for PQ toxicity is
the lung.1 The direct cellular toxicity of PQ is essentially due to
its redox cycle (Fig. 1): PQ is reduced enzymatically, mainly by
the reduced form of nicotinamide adenine dinucleotide
phosphate–cytochrome P-450 reductase, the reduced form of
nicotinamide adenine dinucleotide phosphate–cytochrome c
reductase, and the reduced form of nicotinamide adenine
dinucleotide:ubiquinone oxidoreductase (complex I), to form a
PQ monocation free radical. The PQ monocation free radical is
then rapidly reoxidized in the presence of oxygen, thus resulting
in the generation of the superoxide radical.1 This then sets in the
well-known cascade, leading to generation of the hydroxyl
radical and consequent deleterious effects. Nowadays, no
antidote or efficient treatment of PQ poisoning has been
identified, the survival depending on the amount ingested and
the time elapsed until the patient is submitted to intensive
medical measures to inactivate and eliminate PQ.
The aim of this article is to report a successful clinical
case regarding the intoxication of a young girl who ingested
a potentially lethal dose of PQ.
CASE
A 15-year-old girl voluntarily ingested approximately 50 mL
of a commercialized PQ formulation (20% wt/vol of PQ dichloride
salt), corresponding to nearly 10g of PQ ingested. The weight of the
girl weight was 47 kg. Twenty minutes after ingestion the
adolescent vomited, the gastric contents having a greenish
appearance. She was taken to a local hospital about 2 hours 30
minutes after ingestion. After admission she was immediately
submitted to a gastric lavage with physiologic 0.9% NaCl solution.
Mineral adsorbent (100 g of Fuller earth) was subsequently given to
reduce further absorption of PQ into the bloodstream. The patient
was then transferred to the intensive care unit. She was conscious,
anxious, with a coherent speech, presenting a slightly sinus
tachycardia (around 110 heartbeats min1) and a respiratory rate
approximately 22 cycles min1, with no fever and hemodynami-
cally stable. There was no history of respiratory or other illness.
Chest radiograph, hemogram, and blood chemistry were all normal.
No erosion lesions were noted in the oral cavity. The remainder of
physical examination was unremarkable. The ingestion was
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confirmed by a qualitative sodium dithionite test on a urine sample.
The initial urine colorimetric test showed a dark blue color.
Analysis of urine samples collected at 4, 6, 10, 16, 20, 26, 30,
42, and 50 hours after ingestion revealed values of 102.83
(prehemoperfusion), 87.07 (during hemoperfusion), 11.97 (after
hemoperfusion), 22.99 (prehemoperfusion), 9.45 (after hemoperfu-
sion), 5.75 (prehemoperfusion), 0.25 (after hemoperfusion), 0.35
(prehemoperfusion), and 0.20 mg L1 (after hemoperfusion),
respectively. Fifty-eight hours after ingestion, PQ in the urine was
lower than the quantification limit. The PQ levels in the serum
samples at the same times were lower than the quantification limit
of the method, with the exception of the first, second, and third
sampled times where it was found (3.5, 1.75, and 0.95 mg L1 of
PQ, respectively). Serum and urinary levels of PQ were undetect-
able 20 and 72 hours after ingestion, respectively.
In the face of the severity of the intoxication, with high serum
and urine PQ levels, it was followed an aggressive therapeutic protocol.
The patient was submitted to hemoperfusion during 4 days, in 7
sessions of 3 hours each. The first session was initiated 4 hours after
ingestion. The observed complications were electrolyte disturbances,
with hypokalemia, hypomagnesemia, and hypophosphatemia. Severe
alterations in the coagulation tests due to the heparin used during the
hemoperfusion did not require immediate correction. Only after the last
session was protamine sulfate needed. Thrombocytopenia evolved, but
it was resolved after suspension of hemoperfusion.
Pharmacotherapy was initiated with (1) 15 mg kg1
cyclophosphamide (CP) in 100 mL of a 5% dextrose solution
perfused over 60 minutes once daily after hemoperfusion during
the first 2 days of hospitalization; (2) 15 mg kg1 methylprednis-
olone (MP) in 200 mL of a 5% dextrose solution perfused over 60
minutes and repeated once daily for 3 consecutive days always after
hemoperfusion; (3) 100 mg kg1 desferrioxamine (DFO) in 500 mL
of a 5% dextrose solution in continuous intravenous perfusion at
21 mL hour1 during 24 hours in 1 administration started after the
first hemoperfusion session; (4) 300 vitamin E mg/p.o. twice daily
after hemoperfusion; (5) N-acetylcysteine (NAC) was administered
after the first hemoperfusion session in a dose of 150 mg kg1 in
500 mL of a 5% dextrose solution perfused during 3 hours;
subsequently, it was given 300 mg kg1 in 500 mL of a 5% dextrose
solution in continuous perfusion at 21 mL hour1 during 3 weeks.
After 3 days, MP was suspended, and the patient received
5 mg of intravenous dexamethasone (DX) every 8 hours during the
next 5 days, with posterior withdraw therapy regime for
approximately 20 days. In addition, the patient received prophylaxis
for stress ulcer (40 mg omeprazol, i.v., twice daily) and for
opportunistic infections (one tablet daily containing 800 mg
cotrimoxazol and 160 mg of trimethoprim). The patient did not
develop renal or hepatic failure. No signs of infection were noted
from long-term steroid therapy. Initial pulmonary function tests and
chest radiograph at the time of admission were normal. However,
on day 7, computerized axial tomography (CAT) of the thorax
revealed areas of pulmonary densification, with ground-glass
attenuation at the lung base possibly indicating initial edema as a
sign of fibrosis. Pulmonary function tests also showed alterations in
the CO diffusion. The hospitalization lasted 22 days. At discharge
time CO diffusion test and CAT were all normal. Six months later,
all the parameters were standard.
DISCUSSION
In the present report a successful clinical case is
presented regarding the intoxication of a young girl by a
presumed lethal dose of PQ.
FIGURE 1. Schematic representation of the mechanism of PQ toxicity. A indicates cellular diaphorases. CAT, catalase; FR, Fenton
reaction; Gred, glutathione reductase; GPX, glutathione peroxidase; HWR, Haber-Weiss reaction; PQ+, PQ cation radical; PQ2+,
paraquat; SOD, superoxide dismutase or spontaneously.
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Previous works2,3 reporting human PQ poisoning show
that the plasma and urine concentration within the first 24 and
48 hours postintoxication are good predictors of outcome.
The initial urine colorimetric test showed dark blue color. The
appearance of strongly positive dithionite tests in urine and
the PQ serum concentration 4, 6, and 10 hours after
ingestion2,3 were indicators of a poor prognosis.3 Despite
undetectable levels of PQ in the serum 10 hours after
ingestion, the very high concentration of PQ in urine was
certainly predictive of a fatal outcome.3 According to survival
probability using the criteria of the study by Scherrmann
et al,3 Proudfoot et al,2 and Hart et al,4 the likelihood of
mortality falls into death from pulmonary fibrosis.
Because there are no known antidotes for PQ and there
are no chelating agents capable of binding the PQ in the
blood or other tissues, over the past 40 years, strategies in
the management of PQ poisoning have been directed toward
the modification of the toxicokinetics of the poison by either
decreasing its absorption5 or enhancing its elimination. Such
approaches are intended to prevent the accumulation of PQ
in tissues and include procedures such as induced emesis or
diarrhea, gastric lavage, administration of oral absorbents,
hemodialysis, and hemoperfusion.6 No vomit induction was
performed because the formulation already contained an
emetic, and the young girl vomited, which certainly
contributed to the positive outcome despite the high quantities
of PQ that were absorbed and quantified in the serum and
urine. After admission, she was immediately submitted to a
gastric lavage with physiologic 0.9% NaCl solution, a
successful measure in some cases of heavy PQ poisoning.6
Mineral adsorbent (100 g of Fuller earth) was subsequently
given to reduce further absorption of PQ into the bloodstream.
The supporting references for this therapeutic measure not
only include in vitro7 and in vivo8 studies demonstrating the
strong and tight binding of PQ to this adsorbent but also some
successful cases of PQ poisoning treatment.9 The patient was
then submitted to hemoperfusion, which seems to be an
indispensable treatment for patients with acute PQ poison-
ing,10 increasing the chance of survival if started early within 4
hours after ingestion and showing higher extraction ratios11
for PQ when compared to hemodialysis.
Beside these treatments, additional protective mea-
sures were also adopted: (1) those aimed to prevent the
generation of reactive oxygen species, namely, the effective
control of iron distribution by DFO; (2) those aimed to
scavenge reactive oxygen species (ROS), including the
maintenance of effective levels of antioxidants such as
vitamin E; (3) those aimed to repair the ROS-induced
lesions, particularly the maintenance of effective levels of
glutathione by administrating NAC; and (4) those aimed to
reduce inflammation by DX, MP, CP, and NAC.
Pharmacotherapy was initiated with CP and MP.
Although high doses of CP and DX treatments, including
intravenous CP (5 mg kg1 d1) and DX (24 mg d1) for 14
days have been correlated with 75% survival rate after PQ
poisoning,12 a subsequent study13 did not demonstrate the
usefulness of this approach. Therefore, the efficacy of high-
dose CP and DX in PQ poisoning remains controversial.
Recently, a report14 demonstrated that pulse therapy with CP
and MP might be effective in preventing respiratory failure
and reducing mortality in patients with moderate to severe
PQ poisoning. Pulse therapy with MP is known as a strong
anti-inflammatory treatment in clinical practice,14 suppress-
ing ROS production by neutrophils and macrophages, and in
the arachidonic acid cascade.15
Furthermore, CP exerts a wide range of immunomodu-
latory effects that influence virtually all components of the
cellular and humoral immune response, and reduce the severity
of inflammation,16 therefore contributing to the overall effect.
In addition, CP-induced leukopenia 1 to 2 weeks later may
contribute to reduce pulmonary inflammatory process of PQ-
poisoned patients.12
Taking into account the involvement of ROS in the
toxicity of PQ, compounds that can interfere with their
generation and propagation of oxidative stress may be useful
therapeutical tools in the treatment of PQ poisoning. It has
been shown that DFO can exert its protective effects not only
by iron chelating (and thus inhibiting the PQ-induced
generation of hydroxyl radicals) but also by blocking the
uptake of PQ by the alveolar type II cells.17 Concerning the
use of vitamin E (a-tocopherol), this lipid-soluble vitamin
exerts its antioxidant effects by scavenging free radicals and
stabilizing membranes containing polyunsaturated fatty
acids,18 which may prevent the cytotoxic effects of PQ.
The use of vitamin E is described in several survival cases
after PQ poisoning.19
NAC has also been used with success in massive
PQ poisoning.20 NAC, the acetylated derivate of the amino
acid l-cysteine, was administrated because it is an excellent
source of sulfhydryl groups. NAC is indeed converted in
the body into cysteine, the rate limiting amino acid for
glutathione synthesis, promoting detoxification and acting
directly as a free radical scavenger.21 Exposure of human
alveolar cells in vitro to PQ has been shown to induce
apoptotic cell death, perhaps via oxidative stress mecha-
nisms, this toxic effect being inhibited by NAC, an effect
attributed to the direct scavenging action of its sulfhydryl
group.22 In addition, it was previously shown that
the administration of NAC to PQ-challenged rats delayed
the PQ-induced release of chemoattractants for neutrophils
in the bronchoalveolar lavage fluid and significantly re-
duced the infiltration of inflammatory cells, suggesting
that NAC can also confer its protective effect by delaying
inflammation.23
At the fourth day after intoxication, 5 mg of in-
travenous dexamethasone were administered every 8 hours
during the next 5 days to prevent the inflammation.24
Prolonged therapy with steroids may increase survival in a
refractory late-stage, but not in an early-stage state of adult
respiratory distress syndrome.25 This effect is attributable to
the downregulation of circulating macrophages, as well as of
collagenase activity, and promotion of the proliferation of
type II pneumocytes.25 Therefore, repeated pulse and
continuous steroid therapy may prevent further inflammation
and damage of pulmonary tissues by superoxide anion in
patients affected by severe PQ poisoning.
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In conclusion, the therapeutic protocol followed in the
present clinical case was coincidental with a positive outcome.
We conducted an intensive and aggressive treatment based
on the high ingestion volume, confirmed by the high urine
and serum PQ levels. The prognosis of this intoxicated girl
resembles those patients with moderate to severe poisonings,
which, after a morphologically characterized early destructive
phase of alveolar type I and type II epithelial cells, develop a
second proliferative phase defined by alveolitis, pulmonary
edema, and infiltration of inflammatory cells.1 For this reason
our protocol may not be applied to fulminant intoxications
where multiorgan failure is the main cause of death. It is
hoped that the present therapeutic approach may be valuable
for other intensive care units in the management of this very
common intoxication. Nevertheless, further controlled studies
are required to confirm the usefulness of our protocol.
REFERENCES
1. Onyeama HP, Oehme FW. A literature review of paraquat toxicity. Vet
Hum Toxicol. 1984;26:494–502.
2. Proudfoot AT, Stewart MS, Levitt T, et al. Paraquat poisoning:
significance of plasma-paraquat concentrations. Lancet. 1979;18:
330–332.
3. Scherrmann JM, Houze P, Bismuth C, et al. Prognostic value of plasma
and urine paraquat concentration. Hum Toxicol. 1987;6:91–93.
4. Hart TB, Nevitt A, Whitehead A. A new statistical approach to
the prognostic significance of plasma concentrations. Lancet. 1984;2:
1222–1223.
5. Okonek S, Hofmann A, Henningsen B. Efficacy of gut lavage,
hemodialysis, and hemoperfusion in the therapy of paraquat or diquat
intoxication. Arch Toxicol. 1976;36:43–51.
6. Meredith TJ, Vale JA. Treatment of paraquat poisoning in man: methods
to prevent absorption. Hum Toxicol. 1987;6:49–55.
7. Okonek S, Setyadharma H, Borchert A, et al. Activated charcoal is as
effective as Fuller’s earth or bentonite in paraquat poisoning. Klin
Wochenschr. 1982;60:207–210.
8. Idid SZ, Lee CY. Effects of Fuller’s earth and activated charcoal on oral
absorption of paraquat in rabbits. Clin Exp Pharmacol Physiol.
1996;23:679–681.
9. Clark DG. Inhibition of the absorption of paraquat from the gastro-
intestinal tract by adsorbents. Br J Ind Med. 1971;28:186–188.
10. Hong SF, Yang JO, Lee EY, et al. Effect of haemoperfusion on plasma
paraquat concentration in vitro and in vivo. Toxicol Ind Health.
2003;17–23.
11. Winchester JF. Dialysis and hemoperfusion in poisoning. Adv Ren
Replace Ther. 2002;9:26–30.
12. Addo E, Poon-King T. Leukocyte suppression in treatment of 72
patients with paraquat poisoning. Lancet. 1986;1:1117–1120.
13. Perriens JH, Benimadho S, Kiauw IL, et al. High-dose cyclophospha-
mide and dexamethasone in paraquat poisoning: a prospective study.
Hum Exp Toxicol. 1992;11:129–134.
14. Lin JL, Wei MC, Liu YC. Pulse therapy with cyclophosphamide and
methylprednisolone in patients with moderate to severe paraquat
poisoning: a preliminary report. Thorax. 1996;51:661–663.
15. Yoshida T, Tanaka M, Sotomatsu A, et al. Effect of methylprednisolone-
pulse therapy on superoxide production of neutrophils. Neurol Res.
1999;21:509–512.
16. Fox DA, McCune WJ. Immunosuppressive drug therapy of systemic
lupus erythematosus. Rheum Dis Clin North Am. 1994;20:265–299.
17. Wal NAVd, Smith LL, Oirshot JFv, et al. Effect of iron chelators on
paraquat toxicity in rats and alveolar type II cells. Am Rev Respir Dis.
1992;145:180–186.
18. Burton GW. Vitamin E: molecular and biological function. Proc Nutr
Soc. 1994;53:251–262.
19. Shahar E, Barzilay Z, Aladjem M. Paraquat poisoning in a child: vitamin
E in amelioration of lung injury. Arch Dis Child. 1980;55:830–831.
20. Drault JN, Baelen E, Mehdaoui H, et al. Massive paraquat poisoning.
Favorable course after treatment with n-acetylcysteine and early
hemodialysis. Ann Fr Anesth Reanim. 1999;18:534–537.
21. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-
containing antioxidant: N-acetylcysteine. Respiration. 1986;50:31–42.
22. Cappelletti G, Maggioni MG, Maci R. Apoptosis in human lung
epithelial cells: triggering by paraquat and modulation by antioxidants.
Cell Biol Int. 1998;22:671–678.
23. Hoffer E, Avidor I, Benjaminov O, et al. N-acetylcysteine delays the
infiltration of inflammatory cells into the lungs of paraquat-intoxicated
rats. Toxicol Appl Pharmacol. 1993;120:8–12.
24. Chen GH, Lin JL, Huang YK. Combined methylprednisolone and
dexamethasone therapy for paraquat poisoning. Crit Care Med.
2002;30:2584–2587.
25. Meduri GU, Belenchia JM, Estes RJ, et al. Fibroproliferative phase of
ARDS. Clinical findings and effects of corticosteroids. Chest. 1991;
100:943–952.
540 n 2006 Lippincott Williams & Wilkins
Dinis-Oliveira et al Pediatric Emergency Care  Volume 22, Number 7, July 2006
Copyr ight ' Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
